WO2004042405A3 - Diagnostic et therapeutique pour maladies associees au recepteur 3 couples aux proteines g (gpr3) humain - Google Patents

Diagnostic et therapeutique pour maladies associees au recepteur 3 couples aux proteines g (gpr3) humain Download PDF

Info

Publication number
WO2004042405A3
WO2004042405A3 PCT/EP2003/011687 EP0311687W WO2004042405A3 WO 2004042405 A3 WO2004042405 A3 WO 2004042405A3 EP 0311687 W EP0311687 W EP 0311687W WO 2004042405 A3 WO2004042405 A3 WO 2004042405A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
gpr3
human
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2003/011687
Other languages
English (en)
Other versions
WO2004042405A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Holger Summer filed Critical Bayer Healthcare Ag
Priority to AU2003301892A priority Critical patent/AU2003301892A1/en
Publication of WO2004042405A2 publication Critical patent/WO2004042405A2/fr
Publication of WO2004042405A3 publication Critical patent/WO2004042405A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention présente un GPR3 humain lequel est associé aux maladies hématologiques, aux maladies cardio-vasculaires, à des troubles du système nerveux périphérique et central, à des troubles de la reproduction, à des troubles gastro-entérologiques, des troubles respiratoires, l'inflammation et le cancer. L'invention présente également des dosages permettant l'identification de composés utiles dans le traitement ou la prévention de maladies hématologiques, de maladies cardio-vasculaires, de troubles du système nerveux périphérique et central, de troubles de la reproduction, de troubles gastro-entérologiques, de troubles respiratoires, de l'inflammation et du cancer. L'invention présente également des composés qui se fixent à et/ou activent ou inhibent l'activité du GPR3, et des compositions pharmaceutiques contenant ces composés.
PCT/EP2003/011687 2002-11-04 2003-10-22 Diagnostic et therapeutique pour maladies associees au recepteur 3 couples aux proteines g (gpr3) humain WO2004042405A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003301892A AU2003301892A1 (en) 2002-11-04 2003-10-22 Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 3 (gpr3)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02024572.6 2002-11-04
EP02024572 2002-11-04

Publications (2)

Publication Number Publication Date
WO2004042405A2 WO2004042405A2 (fr) 2004-05-21
WO2004042405A3 true WO2004042405A3 (fr) 2004-09-23

Family

ID=32309309

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/011687 WO2004042405A2 (fr) 2002-11-04 2003-10-22 Diagnostic et therapeutique pour maladies associees au recepteur 3 couples aux proteines g (gpr3) humain

Country Status (2)

Country Link
AU (1) AU2003301892A1 (fr)
WO (1) WO2004042405A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2353604T3 (es) 2004-04-20 2011-03-03 Galapagos N.V. Métodos, composiciones y ensayos de compuestos para inhibir la producción de proteína beta-amiloide.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002637A2 (fr) * 2000-06-30 2002-01-10 Curagen Corporation Nouvelles proteines et acides nucleiques les codant

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002637A2 (fr) * 2000-06-30 2002-01-10 Curagen Corporation Nouvelles proteines et acides nucleiques les codant

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 30 May 2001 (2001-05-30), XP002269756, retrieved from EBI Database accession no. BG825283 *
EGGERICKX D ET AL: "MOLECULAR CLONING OF AN ORPHAN G-PROTEIN-COUPLED RECEPTOR THAT CONSTITUTIVELY ACTIVATES ADENYLATE CYCLASE", BIOCHEMICAL JOURNAL, PORTLAND PRESS, LONDON, GB, vol. 309, no. 3, 1995, pages 837 - 843, XP001012012, ISSN: 0264-6021 *
SONG Z-H ET AL: "MOLECULAR CLONING AND CHROMOSOMAL LOCALIZATION OF HUMAN GENES ENCODING THREE CLOSELY RELATED G PROTEIN-COUPLED RECEPTORS", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 28, no. 2, 1995, pages 347 - 349, XP001011892, ISSN: 0888-7543 *

Also Published As

Publication number Publication date
WO2004042405A2 (fr) 2004-05-21
AU2003301892A1 (en) 2004-06-07
AU2003301892A8 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
WO2005093092A3 (fr) Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44)
WO2004042389A3 (fr) Moyens diagnostiques et therapeutiques destines a des maladies associees a la phosphodiesterase 4d (pde4d) humaine
WO2005040828A3 (fr) Agents de diagnostic et de traitement des maladies associees au recepteur 49 couple aux proteines g (gpr49)
WO2003093816A3 (fr) Diagnostics et therapeutiques pour lutter contre des maladies associees au recepteur de l'oxytocine (oxtr)
WO2004038405A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 43 couple a la proteine g (gpr43)
WO2004042402A3 (fr) Moyens diagnostiques et therapeutiques destines a des maladies associees au mrgx1 humain
WO2004071378A3 (fr) Methodes diagnostiques et therapeutiques relatives a des etats pathologiques lies au recepteur hm74a couple a la proteine g
WO2003095967A3 (fr) Methodes diagnostiques et therapeutiques pour les maladies associees au recepteur 9 des chimiokines (ccr9)
WO2004042405A3 (fr) Diagnostic et therapeutique pour maladies associees au recepteur 3 couples aux proteines g (gpr3) humain
WO2003065044A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a gpr72
WO2004038421A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 41 couple a une proteine g humaine (gpr41)
WO2005031345A3 (fr) Diagnostic et therapeutique de maladies associees au recepteur couple a la proteine g adipor2 (adipor2)
WO2004038407A3 (fr) Diagnostics et medicaments pour maladies associees au recepteur 12 humain couple a la proteine g (gpr12)
WO2004038416A8 (fr) Diagnostic et therapeutique de maladies associees au recepteur 6 couple a la proteine g humain (gpr6)
WO2004015427A3 (fr) Methodes diagnostiques et therapeutiques s'adressant a des maladies associees au recepteur 19 couple a la proteine g (gpr19)
WO2003096020A3 (fr) Diagnostic et traitement de maladies liees au recepteur 8 des chimiokines (ccr8)
WO2004104577A3 (fr) Approches diagnostiques et therapeutiques des maladies associees au recepteur 5-hydroxytryptamine 4 (5-ht4)(serotonine)
WO2004015422A3 (fr) Diagnostic et traitement de maladies associees au recepteur 1 couple a la proteine g (ogr-1) du cancer de l'ovaire
WO2003066077A3 (fr) Outil de diagnostic et therapeutique pour des maladies associees au recepteur de neuromedine u1 (nmu1)
WO2003100433A3 (fr) Diagnostics et therapies pour maladies liees au recepteur 3 de l'arginine vasopressine (avpr3)
WO2004038406A3 (fr) Diagnostic et therapie de maladies associees au recepteur 42 couple a la proteine g (gpr42) humain
WO2003100435A3 (fr) Procede pour diagnostiquer et traiter des maladies associees au recepteur de neuromedine u2 (nmu2)
WO2004071394A3 (fr) Agents de diagnostic et de traitement destines aux maladies associees a hm74 (hm74)
WO2004048978A3 (fr) Procedes pour diagnostiquer et traiter des maladies associees au recepteur 37 couple a la proteine g d'acide biliaire (bg37)
WO2003083135A3 (fr) Diagnostique et therapie de maladies associees au recepteur 2 du neuropeptide ff (npff2)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP